Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Current Deferred Tax Assets (2020)

Terns Pharmaceuticals filings provide 1 years of Current Deferred Tax Assets readings, the most recent being $2.1 million for Q4 2020.

  • Quarterly Current Deferred Tax Assets changed N/A to $2.1 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2020, changed N/A year-over-year, with the annual reading at $2.1 million for FY2020, N/A changed from the prior year.
  • Current Deferred Tax Assets hit $2.1 million in Q4 2020 for Terns Pharmaceuticals.
  • Across five years, Current Deferred Tax Assets topped out at $2.1 million in Q4 2020 and bottomed at $2.1 million in Q4 2020.